The IC50 results indicated that the addition of IL32 increased the IC50 value of TKI drugs in EGFR‐mutated cancer cells treated with CM from YY1‐depleted PCs compared to the placebo‐treated group (Figures S5K,L, Supporting Information). The gene discussed is IL32; the disease is cancer.